RRM1 and urinary bladder carcinoma: Combination therapy with Ad-shRRM1 and GEM specifically induces a synergistic cytotoxicity in RRM1-expressing bladder cancer cells and could achieve the same effect with a reduced dosage of either one of the individual drugs.